CVS Health (CVS) Could Be 28% Undervalued As Its Recovery Narrative Builds

CVS Health (CVS) has jumped back into the spotlight after announcing the latest Caliber Artist Series journals, a small product move that still raises fresh questions about its retail brand power.

Recent trading reflects that mix of headlines and hard numbers. CVS Health shares trade at US$89.35, with a 7 day share price return of 6.56% after a softer 90 day share price return of 8.04% and a 1 year total shareholder return of 18.36% that indicates momentum relative to a longer base.

Scan how CVS Health compares with other large healthcare players showing solid momentum and fundamentals with our hand picked 32 high quality undervalued stocks list.

The recent jump in CVS Health after a mixed few months puts a simple decision in front of you. Is this the moment to commit fresh capital, or does it pay to wait for a cheaper shot at the stock and a wider margin of safety?

Most Popular Narrative: 28% Undervalued

On the narrative view, CVS Health carries a fair value of $124 against the latest close at $89.35, pointing to a wide valuation gap that some investors see as driven more by perception than by current earnings power. According to Andrei_Niculescu, a Simply Wall St Community investor who wrote the narrative, the key issue is how durable that earnings base really is over the next few years.

CVS Health is no longer the broken Aetna plus drugstore story the market used for most of 2024 to 2025. Through the first half of 2026 the company has raised full-year guidance twice, Aetna’s medical benefit ratio has improved, cash flow is running well ahead of plan, and all three operating segments are growing. The stock still trades as if the insurance rebuild is temporary and the PBM is about to be regulated into irrelevance.

See why 5 investors see CVS Health as 28% undervalued.

Result: Fair Value of $124 (UNDERVALUED)

Still, two things could flip this CVS Health story quickly: a sharp medical cost spike or heavier than expected PBM margin pressure would challenge that fair value case.

Find out about the key risks to this CVS Health narrative.

Next Steps

Mixed sentiment around CVS Health is clear here, with both concern and optimism in play. Move quickly, review the same balance of issues, and ground your own view in the detailed breakdown of 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond CVS Health?

If CVS Health has your attention, do not stop there. A few minutes spent broadening your watchlist today could shape your next round of returns.

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CVS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]